Hello, everyone. This is Thomas Kudsk Larsen from the Sanofi IR team. Welcome to the Q2 2025 conference call for investors ...

On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported second-quarter adjusted earnings of $12.89 per share, up 12% ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) said it has signed an asset purchase agreement between Sanofi and a subsidiary of the ...

Shares of European pharmaceutical companies sold off on Friday after President Donald Trump issued letters to 17 companies, ...

Sanofi’s SNY stock has been trading below its 200-day and 50-day moving averages since early June. On June 23, the stock’s closing price of $48.18 was below its 50-day moving average of $50.32 ...

Sanofi plans to initiate a Phase 1 study of KT-485 next year. It has also decided to exercise its participation election right for the IRAK4 target. As per the agreement, Kymera achieved a $20 ...

Sanofi's Riliprubart Secures U.S. Orphan Drug Status For Solid Organ Transplant Rejection June 25, 2025 — 01:39 am EDT Written by RTTNews.com for RTTNews -> ...

Adagene Inc. announced that Sanofi will invest up to $25 million and exercise its option for a third SAFEbody discovery program, furthering their strategic partnership. The investment will fund ...

(RTTNews) - French drug major Sanofi S.A. (SNYNF,SNY) announced that the Ministry of Health, Labour and Welfare in Japan has granted orphan drug designation to riliprubart, a monoclonal antibody ...

Consequently, Sanofi has decided to let go of KT-474, which was being evaluated for the treatment of hidradenitis suppurativa (HS) and atopic dermatitis (AD) in two phase IIb dose-ranging studies.